168 related articles for article (PubMed ID: 33066097)
1. Inclusion Complex of Docetaxel with Sulfobutyl Ether β-Cyclodextrin: Preparation, In Vitro Cytotoxicity and In Vivo Safety.
Ren L; Yang X; Guo W; Wang J; Chen G
Polymers (Basel); 2020 Oct; 12(10):. PubMed ID: 33066097
[TBL] [Abstract][Full Text] [Related]
2. Preparation, optimization of the inclusion complex of glaucocalyxin A with sulfobutylether-β-cyclodextrin and antitumor study.
Ren L; Wang J; Chen G
Drug Deliv; 2019 Dec; 26(1):309-317. PubMed ID: 30896265
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics, efficacy, and safety evaluation of docetaxel/hydroxypropyl-sulfobutyl-β-cyclodextrin inclusion complex.
Huang XX; Zhou CL; Wang H; Chen C; Yu SQ; Xu Q; Zhu YY; Ren Y
AAPS PharmSciTech; 2011 Jun; 12(2):665-72. PubMed ID: 21584856
[TBL] [Abstract][Full Text] [Related]
4. Inclusion complex of erlotinib with sulfobutyl ether-β-cyclodextrin: Preparation, characterization, in silico, in vitro and in vivo evaluation.
Devasari N; Dora CP; Singh C; Paidi SR; Kumar V; Sobhia ME; Suresh S
Carbohydr Polym; 2015 Dec; 134():547-56. PubMed ID: 26428157
[TBL] [Abstract][Full Text] [Related]
5. Inclusion Complex of Isoliquiritigenin With Sulfobutyl Ether-β-Cyclodextrin: Preparation, Characterization, Inclusion Mode, Solubilization, and Stability.
Wu X; Li J; Hu C; Zheng Y; Zhang Y; Li J; Li M; Xiao D; Lu L; Huang Y; Zhang X; Li C
Front Chem; 2022; 10():930297. PubMed ID: 35800032
[TBL] [Abstract][Full Text] [Related]
6. Chloramphenicol/sulfobutyl ether-β-cyclodextrin complexes in an ophthalmic delivery system: prolonged residence time and enhanced bioavailability in the conjunctival sac.
Xu Y; Zhang C; Zhu X; Wang X; Wang H; Hu G; Fu Q; He Z
Expert Opin Drug Deliv; 2019 Jun; 16(6):657-666. PubMed ID: 31033370
[No Abstract] [Full Text] [Related]
7. Characterization and evaluation of a folic acid receptor-targeted cyclodextrin complex as an anticancer drug delivery system.
Xu J; Xu B; Shou D; Qin F; Xu Y; Hu Y
Eur J Pharm Sci; 2016 Feb; 83():132-42. PubMed ID: 26577995
[TBL] [Abstract][Full Text] [Related]
8. Optimization of sulfobutyl-ether-β-cyclodextrin levels in oral formulations to enhance progesterone bioavailability.
Shankar VK; Police A; Pandey P; Cuny ZG; Repka MA; Doerksen RJ; Murthy SN
Int J Pharm; 2021 Mar; 596():120212. PubMed ID: 33493605
[TBL] [Abstract][Full Text] [Related]
9. Design and Evaluation of An Extended-Release Olmesartan Tablet Using Chitosan/Cyclodextrin Composites.
Anraku M; Tabuchi R; Goto M; Iohara D; Mizukai Y; Maezaki Y; Michihara A; Kadowaki D; Otagiri M; Hirayama F
Pharmaceutics; 2019 Feb; 11(2):. PubMed ID: 30781383
[TBL] [Abstract][Full Text] [Related]
10. Decreased Penetration Mechanism of Ranitidine Due to Application of Sodium Sulfobutyl Ether-β-Cyclodextrin.
Yang R; Zhang J; Huang J; Wang X; Yang H; Jin Q
Pharmaceutics; 2023 Nov; 15(11):. PubMed ID: 38004572
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of cholesterol depletion as a marker of nephrotoxicity in vitro for novel β-cyclodextrin derivatives.
Wang H; Xie X; Zhang F; Zhou Q; Tao Q; Zou Y; Chen C; Zhou C; Yu S
Food Chem Toxicol; 2011 Jun; 49(6):1387-93. PubMed ID: 21426923
[TBL] [Abstract][Full Text] [Related]
12. Inclusion complex of lurasidone hydrochloride with Sulfobutylether-β-cyclodextrin has enhanced oral bioavailability and no food effect.
Wang J; Huang B; Dai J; Chen G; Ren L
Am J Transl Res; 2022; 14(3):1495-1506. PubMed ID: 35422944
[TBL] [Abstract][Full Text] [Related]
13. Biodegradable and biocompatible polymeric nanoparticles for enhanced solubility and safe oral delivery of docetaxel: In vivo toxicity evaluation.
Sadaquat H; Akhtar M; Nazir M; Ahmad R; Alvi Z; Akhtar N
Int J Pharm; 2021 Apr; 598():120363. PubMed ID: 33556487
[TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo evaluation of a sulfobutyl ether beta-cyclodextrin enabled etomidate formulation.
McIntosh MP; Schwarting N; Rajewski RA
J Pharm Sci; 2004 Oct; 93(10):2585-94. PubMed ID: 15349968
[TBL] [Abstract][Full Text] [Related]
15. Effect of sulfobutyl ether-β-cyclodextrin and propylene glycol alginate on the solubility of clozapine.
Furuishi T; Sekino K; Gunji M; Fukuzawa K; Nagase H; Endo T; Ueda H; Yonemochi E
Pharm Dev Technol; 2019 Apr; 24(4):479-486. PubMed ID: 30126299
[TBL] [Abstract][Full Text] [Related]
16. Enhanced solubility of guanosine by inclusion complexes with cyclodextrin derivatives: Preparation, characterization, and evaluation.
Mohandoss S; Atchudan R; Immanuel Edison TNJ; Mandal TK; Palanisamy S; You S; Napoleon AA; Shim JJ; Lee YR
Carbohydr Polym; 2019 Nov; 224():115166. PubMed ID: 31472864
[TBL] [Abstract][Full Text] [Related]
17. Partial inclusion complex assisted crosslinked β-cyclodextrin nanoparticles for improving therapeutic potential of docetaxel against breast cancer.
Jain S; Desai MR; Nallamothu B; Kuche K; Chaudhari D; Katiyar SS
Drug Deliv Transl Res; 2022 Mar; 12(3):562-576. PubMed ID: 33774776
[TBL] [Abstract][Full Text] [Related]
18. Thermosensitive
Gözcü S; Polat KH
Turk J Pharm Sci; 2023 May; 20(2):78-83. PubMed ID: 37161283
[TBL] [Abstract][Full Text] [Related]
19. Cyclodextrin based bone regenerative inclusion complex for resveratrol in postmenopausal osteoporosis.
Shah AA; Shah A; Lewis S; Ghate V; Saklani R; Narayana Kalkura S; Baby C; Singh PK; Nayak Y; Chourasia MK
Eur J Pharm Biopharm; 2021 Oct; 167():127-139. PubMed ID: 34329710
[TBL] [Abstract][Full Text] [Related]
20. Influence of sulfobutyl ether beta-cyclodextrin (Captisol) on the dissolution properties of a poorly soluble drug from extrudates prepared by hot-melt extrusion.
Fukuda M; Miller DA; Peppas NA; McGinity JW
Int J Pharm; 2008 Feb; 350(1-2):188-96. PubMed ID: 17920217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
